This trial is evaluating whether PD-0325901 will improve 2 primary outcomes and 3 secondary outcomes in patients with Tumors, Solid. Measurement will happen over the course of 2 Years.
This trial requires 139 total participants across 1 different treatment group
This trial involves a single treatment. PD-0325901 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"curative treatment of carcinoma, non-small-cell lung is possible. However, curative treatment would often be only palliative. More information on prognostic factors and better treatment of lung cancer have to be investigated in the future." - Anonymous Online Contributor
"The overall rate of bronchiolar carcinoma is 15.3% in males, and 15.0% in females older than fifty years. Carcinoma diagnosed later were associated with low risk of mortality from lung cancer. Age and chronic obstructive pulmonary disease (COPD) were independent risk factors for bronchiolar carcinoma. Carcinoma, non-small-cell lung, was the most common form of lung cancer." - Anonymous Online Contributor
"The incidence of all lung cancer and NSCLC in the USA remains relatively static over time. Although the overall trend has remained upward over the past 4 decades, there was no apparent trend during the last 8-10 years (1983-1991). The highest incidence rate of all malignant respiratory diseases was observed in African Americans of all age groups. The incidence of all malignant respiratory diseases remains highest in people younger than 40 years, and there was no apparent trend over time (1983-1991). The highest incidence rate of NSCLC is observed in non-Hispanic whites and African Americans of all age groups; age at time of diagnosis was positively associated with survival in all groups." - Anonymous Online Contributor
"The prevalence of various environmental and behavioral risk factors increases with age, particularly among men. However, the overall age-adjusted prevalence of specific risk factors was less than expected among age groups younger than 75 years." - Anonymous Online Contributor
"As with non-cancerous lesions, cancer treatment depends on the extent of disease and is dependent on how advanced the tumor is. If the tumor responds to surgery, then adjuvant therapy is often prescribed. If the tumor is unresectable, then chemotherapy and/or radiation can be used to delay or prevent the progression of the disease. If the tumor responds to either adjuvant therapy or surgery, then postoperative radiation may be recommended. If there is no response to either adjuvant therapy or surgery, then definitive therapy with radiation or chemotherapy alone is commonly prescribed." - Anonymous Online Contributor
"A patient with lung cancer need to consult their doctor regularly, and those with symptoms need to consult other physicians in their region. We need to educate the general public on smoking and smoking habits, on lung cancer and its signs, and on lung cancer prevention." - Anonymous Online Contributor
"Pd-0325901 has been used at doses up to 1200 mg twice per day for various indications in a clinical context, without severe adverse effects at either dose. Although uncommon at those dosages, the side effects observed in this study are consistent with the clinical experience with pd-0325901 as a biopharmaceutical." - Anonymous Online Contributor
"The treatment for NSCLC seems to be more individualized. In particular, some clinical trial trials have shown a better survival from adjuvant chemotherapy in female participants. For example, the NCCTG phase III study showed more patients in which platinum-based chemotherapy was the treatment compared with nonplatinum-based chemotherapy. Findings from a recent study will help clinicians to counsel patients and decide whether to start adjuvant chemotherapy. As some important patients for adjuvant chemotherapy would not be eligible for some clinical trials, it is mandatory to carry out more individualized studies. In addition, more prospective clinical studies are required to show the effect of therapy in NSCLC according to the stage of disease." - Anonymous Online Contributor
"This paper illustrates the incidence of cancer in the population of Buenos Aires, Argentina, and discusses factors related to this morbidity. The study shows that the disease-free survival rate of patients suffering from pulmonary carcinoma is extremely low in the first six months and only increases a bit over the following years." - Anonymous Online Contributor
"Pd-0325901 is a potent CDK2 kinase inhibitor with antiproliferative activity in human cancer and preclinical murine tumors. Pd-0325901 might have a potential as a target for novel treatments in many solid tumor entities that have been shown to display overexpression of CDK2, including colon, ovarian, breast, and lung." - Anonymous Online Contributor
"For the first time, a representative series of carcinoma cases reported in the literature was reviewed, with an average age of 69 +/- 11.4 yr for both genders. The average age of carcinomas, other than lung adenocarcinoma, is much higher than that of other solid adenocarcinomas reported in the literature." - Anonymous Online Contributor
"Results from a recent paper suggests that PD-0332598 is most commonly and routinely used in combination with most other chemotherapies; therefore, it is important to study the most frequently used pd-0332598 combinations." - Anonymous Online Contributor